methyl xylopyranoside: RN given refers to (beta-D)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 99057 |
| SCHEMBL ID | 29253 |
| SCHEMBL ID | 22030605 |
| SCHEMBL ID | 23549931 |
| SCHEMBL ID | 23867729 |
| MeSH ID | M0144208 |
| Synonym |
|---|
| nsc126704 |
| 36793-06-3 |
| nsc-126704 |
| nsc1975 |
| arabinopyranoside, .beta.-d- |
| nsc-1975 |
| methyl .beta.-d-arabinopyranoside |
| nsc170227 |
| nsc-170227 |
| methyl .beta.-d-xylopyranoside |
| methyl .beta.-d-xyloside |
| arabinopyranoside, .beta.-l- |
| nsc-25272 |
| nsc25272 |
| ribopyranoside, .beta.-d- |
| nsc232024 |
| nsc-232024 |
| NCIOPEN2_000671 |
| lyxopyranoside, .alpha.-d- |
| nsc-78525 |
| nsc78525 |
| .alpha.-d-lyxopyranoside, methyl |
| methyl .alpha.-d-lyxopyranoside |
| 3795-69-5 |
| nsc400273 |
| arabinopyranoside, .alpha.-d- |
| 7404-24-2 |
| nsc-400273 |
| nsc403453 |
| nsc-403453 |
| methyl .alpha.-d-arabinopyranoside |
| methyl xylopyranoside |
| methyl pentopyranoside |
| nsc 170227 |
| nsc 170206 |
| beta-d-xyloside, methyl |
| beta-d-xylopyranoside, methyl |
| einecs 210-289-7 |
| FT-0671506 |
| FT-0633861 |
| FT-0628913 |
| SCHEMBL29253 |
| methyl-alpha-d-xylopyranoside |
| AKOS030212691 |
| FT-0698540 |
| methyl-b-l-arabinopyranoside approx. |
| 1-ome-alpha-d-xyl |
| (2s,3s)-trans-3-methyloxirane-2-methyl4-nitrobenzoate |
| DTXSID60939589 |
| SCHEMBL22030605 |
| A868783 |
| SCHEMBL23549931 |
| SCHEMBL23867729 |
| a-d-lyxopyranoside, methyl |
| alpha-methyl-l-arabinopyranoside |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.27) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||